IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that Radius VSM™, a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510(k) clearance. Designed on ...

As I watched my alma mater The Ohio State University last month battle desperately against Michigan in their annual football game, I felt my pulse rate rising. When I checked my watch, sure enough the ...

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), today announced that the Masimo W1 ® Sport advanced health tracking wearable is gaining a powerful new feature: scientifically based sleep ...

Apple convinced a federal jury on Friday that health monitoring tech company Masimo’s smartwatches infringe two of its design patents. The jury, in Delaware, agreed with Apple that Masimo’s W1 and ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

On March 22, 2024, Masimo MASI Corporation (NASDAQ NDAQ: MASI, $144.91, Market Capitalisation: $7.7 billion), a global leader in non-invasive monitoring technologies and audio products, announced that ...

The stock price of Masimo Corporation, a medical devices company best known for its remote patient monitoring systems, reached its all-time high of $287 just last week before a recent decline resulted ...

Masimo (MASI) shares soared 8.7% in the last trading session to close at $121.42. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q2, starting with Masimo ...

Masimo (NASDAQ:MASI) will release its quarterly earnings report on Tuesday, 2025-11-04. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Masimo to report an ...

The legal woes of the Apple Watch are continuing, as Apple has been hit with a $634 million verdict in a trial over alleged infringement of Masimo's blood oxygen monitoring patents. Masimo has ...